JPH203 is a potent and selective L-type amino acid transporter 1 inhibitor (LAT1), used for cancer research.
JPH203 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Xenopus oocytes
1 µM
30 minutes
To evaluate the inhibitory effect of JPH203 on LAT1
Nat Commun. 2025 Feb 14;16(1):1635.
KKU-055
30 µM
15 or 30 minutes
To investigate the effect of JPH203 on intracellular amino acid levels of LAT1 substrates in BTC cell lines, and found that JPH203 treatment significantly decreased the intracellular levels of LAT1 substrates.
Cancer Metab. 2022 Nov 10;10(1):18.
KKU-100
30 µM
15 or 30 minutes
To investigate the effect of JPH203 on intracellular amino acid levels of LAT1 substrates in BTC cell lines, and found that JPH203 treatment significantly decreased the intracellular levels of LAT1 substrates.
Cancer Metab. 2022 Nov 10;10(1):18.
KKU-213
30 µM
15 or 30 minutes
To investigate the effect of JPH203 on intracellular amino acid levels of LAT1 substrates in BTC cell lines, and found that JPH203 treatment significantly decreased the intracellular levels of LAT1 substrates.
Cancer Metab. 2022 Nov 10;10(1):18.
MCF7 cells
0.02 –20 μg/mL
24 hours
To evaluate the anticancer effect of JPH203 in combination with lapatinib, results showed that JPH203 significantly enhanced the anticancer effect of lapatinib.
Bioact Mater. 2021 Jul 14;9:15-28.
T47D cells
0.02 –20 μg/mL
24 hours
To evaluate the anticancer effect of JPH203 in combination with lapatinib, results showed that JPH203 significantly enhanced the anticancer effect of lapatinib.
Bioact Mater. 2021 Jul 14;9:15-28.
RAW 264.7 cells
20 µM
24 hours
To evaluate the effect of JPH203 on M1 macrophage polarization, results showed that JPH203 significantly downregulated the mRNA levels of pro-inflammatory factors (iNOS, TNF-α, and IL-1β) and upregulated the mRNA levels of anti-inflammatory factors (IL-10 and Arg-1) in M1 macrophages.
Adv Sci (Weinh). 2024 Jun;11(22):e2400713.
Rat Cartilage Cells (RCC)
20 µM
24 hours
To evaluate the protective effect of JPH203 on chondrocytes, results showed that IgG/BRJ significantly suppressed ROS production in RCC and reduced the expression of pro-inflammatory factors, enhancing the metabolic activity of chondrocytes.
Adv Sci (Weinh). 2024 Jun;11(22):e2400713.
Human umbilical vein endothelial cells (HUVECs)
50 µM
24 hours
JPH203 inhibited the proliferation, migration, invasion, and tube formation of HUVECs, indicating that LAT1 plays a crucial role in angiogenesis.
J Exp Clin Cancer Res. 2020 Nov 30;39(1):266.
8505c
10 µM
48 hours
To evaluate the effect of JPH203 on thyroid cancer cell proliferation and mTORC1 activity, results showed that JPH203 significantly reduced cell proliferation and mTORC1 signaling.
J Exp Clin Cancer Res. 2018 Sep 21;37(1):234.
SW1736
10 µM
48 hours
To evaluate the effect of JPH203 on thyroid cancer cell proliferation and mTORC1 activity, results showed that JPH203 significantly reduced cell proliferation and mTORC1 signaling.
J Exp Clin Cancer Res. 2018 Sep 21;37(1):234.
K1
10 µM
48 hours
To evaluate the effect of JPH203 on thyroid cancer cell proliferation and mTORC1 activity, results showed that JPH203 significantly reduced cell proliferation and mTORC1 signaling.
J Exp Clin Cancer Res. 2018 Sep 21;37(1):234.
CCRF-CEM cells
10 µM
48 hours
To evaluate the cytotoxic effect of JPH203 on CCRF-CEM cells, results showed that JPH203 significantly reduced cell viability.
Cancer Metab. 2018 Mar 8;6:1.
MDA MB231 cells
10 µM
48 hours
To evaluate the cytotoxic effect of JPH203 on MDA MB231 cells, results showed that JPH203 had a minor cytotoxic effect on MDA MB231 cells.
Cancer Metab. 2018 Mar 8;6:1.
Pancreatic cancer MIA PaCa-2 cells
3 µM
72 hours
To evaluate the inhibitory effects of JPH203 combined with cytotoxic anticancer drugs on cell growth, the results showed that JPH203 combined with all tested cytotoxic anticancer drugs significantly inhibited cell growth, especially when combined with gemcitabine.
Cancer Cell Int. 2023 Jun 15;23(1):116.
Pancreatic cancer HPAC cells
6 µM
72 hours
To evaluate the inhibitory effects of JPH203 combined with gemcitabine on cell growth, the results showed that the combination significantly inhibited cell growth.
Cancer Cell Int. 2023 Jun 15;23(1):116.
Pancreatic cancer PANC-1 cells
30 µM
72 hours
To evaluate the inhibitory effects of JPH203 combined with gemcitabine on cell growth, the results showed that the combination significantly inhibited cell growth.
Cancer Cell Int. 2023 Jun 15;23(1):116.
Pancreatic cancer SUIT-2 cells
12 µM
72 hours
To evaluate the inhibitory effects of JPH203 combined with gemcitabine on cell growth, the results showed that the combination significantly inhibited cell growth.
Cancer Cell Int. 2023 Jun 15;23(1):116.
Biliary tract cancer HuCCT1 cells
1.3 µM
72 hours
To evaluate the inhibitory effects of JPH203 combined with gemcitabine on cell growth, the results showed that the combination significantly inhibited cell growth.
Cancer Cell Int. 2023 Jun 15;23(1):116.
Biliary tract cancer KKU-055 cells
0.9 µM
72 hours
To evaluate the inhibitory effects of JPH203 combined with gemcitabine on cell growth, the results showed that the combination significantly inhibited cell growth.
Cancer Cell Int. 2023 Jun 15;23(1):116.
Biliary tract cancer KKU-100 cells
8 µM
72 hours
To evaluate the inhibitory effects of JPH203 combined with gemcitabine on cell growth, the results showed that the combination significantly inhibited cell growth.
Cancer Cell Int. 2023 Jun 15;23(1):116.
Biliary tract cancer KKU-213 cells
7 µM
72 hours
To evaluate the inhibitory effects of JPH203 combined with gemcitabine on cell growth, the results showed that the combination significantly inhibited cell growth.
Cancer Cell Int. 2023 Jun 15;23(1):116.
LNCaP
10 µM
96 hours
To evaluate the effect of JPH203 on thyroid cancer cell proliferation and mTORC1 activity, results showed that JPH203 significantly reduced cell proliferation and mTORC1 signaling.
J Exp Clin Cancer Res. 2018 Sep 21;37(1):234.
THP1
40 µM
96 hours
To evaluate the antileukemic effect of JPH203 on THP1 cells, the results showed that JPH203 significantly reduced the survival rate of THP1 cells.
Blood Adv. 2023 Dec 26;7(24):7525-7538.
NB4
40 µM
96 hours
To evaluate the antileukemic effect of JPH203 on NB4 cells, the results showed that JPH203 significantly reduced the survival rate of NB4 cells.
Blood Adv. 2023 Dec 26;7(24):7525-7538.
U937
40 µM
96 hours
To evaluate the antileukemic effect of JPH203 on U937 cells, the results showed that JPH203 significantly reduced the survival rate of U937 cells.
Blood Adv. 2023 Dec 26;7(24):7525-7538.
K562
40 µM
96 hours
To evaluate the antileukemic effect of JPH203 on K562 cells, the results showed that JPH203 significantly reduced the survival rate of K562 cells.
Blood Adv. 2023 Dec 26;7(24):7525-7538.
786-O cells
100 µM
JPH203 significantly reduced phospho-mTOR levels in 786-O and ACHN cells but had a marginal effect on phospho-mTOR levels in 786-O: CLDN10A and ACHN: CLDN10A cells.
Cell Commun Signal. 2024 Dec 5;22(1):588.
ACHN cells
100 µM
JPH203 significantly reduced phospho-mTOR levels in 786-O and ACHN cells but had a marginal effect on phospho-mTOR levels in 786-O: CLDN10A and ACHN: CLDN10A cells.
Cell Commun Signal. 2024 Dec 5;22(1):588.
JPH203 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
MLL-AF9 mouse model
40 μM
Not used
Not used
Blood Adv. 2023 Dec 26;7(24):7525-7538.
BALB/c mice
4T1 subcutaneous fat pad tumor model
Injection
10 mg
Every two days for 28 days
To study the effect of JPH203 combined with anti-PD-1 antibody treatment on tumor progression and immune cell infiltration
Front Immunol. 2023 Sep 4;14:1251643
Rats
Anterior cruciate ligament transection (ACLT)-induced osteoarthritis model
Intra-articular injection
100 μL
Every 5 days for 30 days
To evaluate the therapeutic effect of IgG/BRJ in the osteoarthritis model, results showed that IgG/BRJ significantly promoted cartilage repair, reduced synovial inflammation, and increased the number of M2 macrophages.
Adv Sci (Weinh). 2024 Jun;11(22):e2400713.
Nude mice
MCF7 tumor model
Intravenous injection
2 mg/kg
Every 2 days for 6 days
To evaluate the in vivo anticancer effect of JPH203 in combination with lapatinib, results showed that LJ@Trp-NPs significantly inhibited tumor growth.
Bioact Mater. 2021 Jul 14;9:15-28.
C57BL/6J mice
Matrigel plug assay
Intravenous injection
25 mg/kg/day
Once daily for 14 days
JPH203 significantly suppressed the growth of MIA PaCa-2 xenograft tumors and reduced intratumoral blood vessel density, indicating that inhibiting angiogenesis by targeting endothelial LAT1 can suppress tumor growth.
J Exp Clin Cancer Res. 2020 Nov 30;39(1):266.
Mice
BRAFV600E/PIK3CAH1047R double-mutant mouse model
Intraperitoneal injection
50 mg/kg/day
5 consecutive days/week for 45 days
To evaluate the effect of JPH203 on thyroid cancer tumor growth in vivo, results showed that JPH203 significantly inhibited tumor growth.
搜索
